Antigenics Inc. (New York) Data from Investigator-Sponsored Trial of Oncophage(R) Cancer Vaccine in Glioma Presented at American Association of Neurological Surgeons Annual Meeting

WASHINGTON--(BUSINESS WIRE)--Antigenics Inc. (NASDAQ: AGEN) today announced an oral presentation of updated data from a Phase 1/2 investigator-sponsored trial of the company’s investigational cancer vaccine Oncophage® (vitespen) in recurrent, high-grade glioma at the 75th annual meeting of the American Association of Neurological Surgeons (AANS; abstract #606). Preliminary results from the study, being conducted at the Brain Tumor Research Center at the University of California, San Francisco, showed that Oncophage vaccination was associated with significant tumor-specific immune response in all 12 treated patients from baseline (P < .001), as determined using three separate immune response assessments. Of the 12 patients treated, four continue to receive Oncophage and eight have completed treatment and are evaluable for overall survival. Seven of these eight evaluable patients have exceeded the historical median benchmark of 6.5 months survival from time of recurrence.